During the past decade, MultiCare Institute for Research & Innovation conducted 110 clinical trials. In the 10-year time frame, 110 clinical trials started and 41 clinical trials were completed, i.e. on average, 37.3% percent of trials that started reached the finish line to date. In the past 5 years, 55 clinical trials started and 38 clinical trials were completed. i.e. 69.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MultiCare Institute for Research & Innovation" #1 sponsor was "Pfizer" with 7 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Celgene" with 4 trials sponsored, "Eisai Inc." with 4 trials sponsored and "Eli Lilly and Company" with 4 trials sponsored. Other sponsors include 86 different institutions and companies that sponsored additional 76 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MultiCare Institute for Research & Innovation" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Iqvia Pty Ltd" with 2 trials as a collaborator, "Regulatory and Clinical Research Institute Inc" with 2 trials as a collaborator and "Biogen" with 1 trials as a collaborator. Other collaborators include 19 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "MultiCare Institute for Research & Innovation" are "Dravet Syndrome" (7 trials), "Multiple Sclerosis, Relapsing-Remitting" (4 trials), "Breast Cancer" (3 trials), "Growth Hormone Deficiency" (3 trials) and "Lennox Gastaut Syndrome" (3 trials). Many other conditions were trialed in "MultiCare Institute for Research & Innovation" in a lesser frequency.

Most popular intervention types in "MultiCare Institute for Research & Innovation" are "Drug" (89 trials), "Biological" (11 trials), "Other" (10 trials), "Device" (9 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (33 trials), "Ocrelizumab" (4 trials), "ZX008 (Fenfluramine Hydrochloride)" (4 trials), "Atezolizumab" (3 trials) and "Gemcitabine" (3 trials). Other intervention names were less common.

The vast majority of trials in "MultiCare Institute for Research & Innovation" are 110 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "MultiCare Institute for Research & Innovation". undefined are not yet recruiting, 29 are recruiting, 22 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 49 completed trials in MultiCare Institute for Research & Innovation, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in MultiCare Institute for Research & Innovation, 8 "Phase 1" clinical trials were conducted, 30 "Phase 2" clinical trials and 59 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 9 trials that are defined as “Not Applicable".